Agitation is one of the most distressing symptoms experienced by people living with dementia. It can affect quality of life, increase caregiver burden, and often lead to the use of medications that carry significant side effects.

New research has brought renewed attention to the potential role of medical cannabis for dementia agitation. A recent Phase II clinical trial found that a pharmaceutical formulation containing THC and CBD significantly reduced agitation in people with advanced dementia.

Although the findings are promising, it is important to understand what the study showed, what it did not show, and what it means for patients and families considering cannabis-based treatments for dementia-related agitation.

Key Takeaways

• Agitation is a common behavioural symptom of dementia.
• A recent Phase II clinical trial investigated a medical cannabis formulation containing THC and CBD.
• Researchers reported significant improvements in agitation compared with placebo.
• The treatment did not cure or slow dementia.
• Larger studies are still needed before medical cannabis becomes a routine treatment for dementia-related agitation.

What is agitation in dementia?

Agitation is one of the most common behavioural and psychological symptoms of dementia (BPSD).

It may include:

• Restlessness
• Pacing
• Irritability
• Repetitive speech
• Verbal aggression
• Physical aggression
• Emotional distress
• Resistance to care

These symptoms often occur because dementia affects the parts of the brain responsible for emotion, communication and behaviour. Pain, confusion, unfamiliar surroundings and unmet needs can also contribute.

For many families, agitation becomes one of the most challenging aspects of caring for someone with dementia.

Can medical cannabis help dementia agitation?

A recent clinical trial suggests it may.

Researchers investigated whether a pharmaceutical-grade medical cannabis formulation containing THC (tetrahydrocannabinol) and CBD (cannabidiol) could reduce agitation in people living with advanced dementia.

The study included 120 hospice-eligible participants with Alzheimer’s disease and other forms of advanced dementia who were experiencing clinically significant agitation.

Participants received either:

• a THC/CBD oral formulation, or
• a placebo.

The study was:

• Phase II
• Randomised
• Double-blind
• Placebo-controlled

These types of trials are considered among the highest-quality methods for evaluating new treatments for dementia agitation.

What did the study find about cannabis for dementia agitation?

The results were encouraging.

Researchers found that:

• Improvements in agitation appeared within two weeks.
• Benefits continued throughout the 12 week study.
• Approximately 87% of participants receiving the cannabinoid treatment improved, compared with 24% of those receiving placebo.

The researchers concluded that cannabinoid-based medicines may offer a promising approach to managing agitation in advanced dementia, although further research is still required.

How might THC and CBD help agitation in dementia?

Researchers are continuing to investigate how cannabinoids interact with the endocannabinoid system, a network of receptors involved in regulating mood, memory, sleep, pain perception and behaviour.

It is thought that THC and CBD may influence some of the brain pathways involved in agitation and emotional regulation.

However, exactly how cannabinoids reduce agitation in dementia is not yet fully understood, and more research is needed before firm conclusions can be drawn.

Current treatments for dementia-related agitation

Treatment usually begins with non-drug approaches.

These may include:

• Maintaining familiar routines
• Identifying possible causes of distress
• Environmental adjustments
• Music therapy
• Reminiscence therapy
• Person-centred care

When symptoms become severe, clinicians may consider medications such as antipsychotics or sedatives.

While these medicines can help some patients, they also carry important risks, particularly in older adults, including increased sedation, falls and cardiovascular complications.

This is one reason researchers continue to explore whether medical cannabis could become another treatment option for dementia agitation.

Does medical cannabis treat dementia?

No.

The recent trial did not show that medical cannabis treats, reverses or slows dementia itself.

Instead, it investigated whether a specific pharmaceutical formulation containing THC and CBD could reduce one symptom of dementia: agitation.

This distinction is important.

Current evidence suggests cannabinoids may have potential for managing certain symptoms in some patients, but there is currently no evidence that medical cannabis cures Alzheimer’s disease or other forms of dementia.

Is medical cannabis available for dementia agitation in the UK?

Medical cannabis can be prescribed legally in the UK by specialist doctors in certain circumstances.

However, dementia is not currently an established indication, and cannabinoid medicines are not routinely prescribed specifically for agitation associated with dementia.

Any treatment decision should always be made on an individual basis following a specialist clinical assessment.

What does this research mean for patients and families?

The findings offer cautious optimism.

Agitation can significantly affect quality of life for people living with dementia while placing considerable emotional and physical demands on caregivers.

Although more research is needed before cannabinoid medicines become part of routine dementia care, studies such as this help expand our understanding of where medical cannabis may have a role in symptom management.

Future Phase III clinical trials will be important in confirming whether these early findings can be replicated in larger groups of patients.

Frequently Asked Questions

Can medical cannabis cure dementia?

No. There is currently no evidence that medical cannabis cures, reverses or slows dementia.

Can CBD help dementia agitation?

CBD is being investigated for several symptoms associated with dementia, including agitation. Research is ongoing, and more evidence is needed before conclusions can be drawn.

Does THC reduce agitation in dementia?

Recent clinical research suggests that a pharmaceutical combination of THC and CBD may reduce agitation in some people with advanced dementia. Larger studies are still required.

Is medical cannabis prescribed for dementia in the UK?

Medical cannabis is not routinely prescribed specifically for dementia. Treatment decisions are made individually by specialist clinicians where appropriate.

The Bottom Line on Medical Cannabis for Dementia Agitation

Recent research suggests that medical cannabis for dementia agitation is an area of growing scientific interest.

A Phase II clinical trial found that a pharmaceutical formulation containing THC and CBD significantly reduced agitation in people with advanced dementia compared with placebo. While these findings are encouraging, larger clinical trials are needed before cannabinoid medicines become part of standard dementia care.

As research continues, studies like these help build the evidence base for where medical cannabis may have a role in managing complex symptoms and improving quality of life for some patients.

References: AAIC 2026: LIBBY trial, THC and CBD for agitation in late-stage dementia